To prevent rebound weight gain and associated inflammation—which is particularly detrimental for cancer survivors—patients should not stop GLP-1s abruptly. Instead, a slow, methodical 20-week taper is recommended, with close monitoring to ensure weight stability before full discontinuation.
A novel pilot study, the TRIMM trial, is investigating if a GLP-1 agonist can eliminate minimal residual disease (MRD), as measured by ctDNA, in breast cancer patients with obesity. This frames a metabolic intervention as a potential anti-cancer therapeutic, moving beyond its role in supportive care.
Early retrospective data from major cancer centers suggests patients on hormone therapy experience less weight loss with GLP-1 agonists. This indicates a potential drug interaction that may require clinicians to more closely monitor weight trends and consider dose adjustments for this patient population.
Unpublished data from a UT Southwestern group indicates that using GLP-1 agonists during a specific neoadjuvant chemo-immunotherapy regimen (Keynote 522) may significantly reduce pathologic complete response rates. This critical safety concern is prompting forthcoming ESMO guidelines recommending against their concurrent use.
Beyond weight management, preliminary evidence suggests GLP-1 agonists may help with vasomotor symptoms (hot flashes) and arthralgia (joint pain). The proposed mechanism is indirect, likely through reduced inflammation from fat loss and less mechanical load on joints, representing a novel potential benefit for patients.